Bulbine natalensis to Improve Testosterone - Quick Reference Sheet

Bulbine natalensis to Improve Testosterone

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Bulbine natalensis stem extract can raise testosterone and enhance male sexual behavior in rats at mid-range doses; human hormone trials are absent. The same animal doses stress liver and kidney and worsen blood lipids, while one short human safety study was largely reassuring. Longevity-focused use supports only short, laboratory-monitored evaluation—not a proven lifestyle or medical-therapy substitute. (Full Review)

Protocol

Dose
650 mg/day total
325 mg morning + 325 mg ~6 hours later (human safety regimen, ProLensis™)
Course
28 days
Human-studied safety regimen length; efficacy not reported
Weight-based estimate
~8 mg/kg extract
Examine-style conversion from rat 50 mg/kg (~550 mg at 68 kg; ~730 mg at 91 kg)
Time to effect
Animal hormone & behavior
Days to 2 weeks
Hormone and mating-behavior changes in rats
Human testosterone
Unknown
Onset unknown; laboratory reassessment at 2–4 weeks

Benefits

Contraindications
  • Pregnancy and attempted conception (female)
  • Breastfeeding
  • Active liver disease, unexplained enzyme elevation, or advanced chronic kidney disease
  • Planned surgery within 2 weeks
  • Children and adolescents
  • Unable or unwilling to obtain baseline and follow-up hormone and organ labs
Key Interactions
  • Prescription CYP3A4 substrates (e.g., midazolam, certain statins such as simvastatin/atorvastatin, some calcium-channel blockers, calcineurin inhibitors)
  • Prescription CYP2C9 substrates (e.g., warfarin, phenytoin, some NSAIDs such as celecoxib, sulfonylureas)
  • CYP1A2 / CYP2B6 / P-gp substrates (e.g., clopidogrel activation pathways, some antidepressants, digoxin)
  • Digoxin and cardiac glycosides
  • Anticoagulant / antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin, etc.)
  • Added testosterone or potent androgenic agents
  • Other testosterone-support combinations (e.g., high-dose fenugreek, tongkat ali, fadogia, aromatase inhibitors)

Risk & Side Effects

  • High:
  • Medium: Liver and kidney marker and tissue-structure stress
  • Low: Adverse lipid shift; white-cell and blood-cell shifts; high-dose behavioral suppression; herb–drug interaction via CYP enzymes and drug-export pumps; heavy-metal contamination of crude market material; early pregnancy loss risk at high dose
  • Speculative: Aggression, acne, or testicular discomfort

Monitoring

Marker Target Why
Total testosterone ~500–900 ng/dL (lab-specific) Primary efficacy endpoint
Free testosterone Upper half of lab reference Bioavailable testosterone signal
SHBG Mid lab range Interprets free fraction
Estradiol (sensitive) Roughly 20–40 pg/mL (individualize) Testosterone-to-estrogen balance
LH Low–mid reference if primary testicular failure absent Confirms pituitary drive if testosterone rises
FSH Lab reference Sperm-production axis context
ALT Often <30 U/L functional Liver-cell injury screen
AST Often <30 U/L functional Liver-cell injury screen
GGT Low–mid reference; preference toward lower Bile-flow, alcohol, or other liver-stress signals
ALP Lab reference Bile-duct or bone enzyme forms
Total bilirubin Lab reference Liver clearance function
Creatinine / eGFR eGFR ≥90 mL/min/1.73 m² preferred Kidney filtration safety
Fasting lipid panel TG <100–150 mg/dL; HDL adequate; LDL individualized Animal data worsened lipids
CBC (hematocrit) Hematocrit typically <50–52% Androgen-related excess red-blood-cell mass screen

Cadence: Baseline before first dose; repeat at 2–4 weeks, near 8 weeks if continued, then every 3 months during extended use—or sooner if symptoms arise

Qualitative Assessment

  • Libido and morning erections
  • Training performance and recovery
  • Mood, irritability, and sleep quality
  • Skin (acne), hair shedding, breast tenderness
  • Right-upper-quadrant discomfort, urine color, unusual bruising